2026 Metabolic dysfunction-associated steatohepatitis indication strategy covering epidemiology, THR-beta biology, active trials, transactions, unmet need,…

2026 Alcohol-associated cirrhosis indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market…

2026 Hepatic encephalopathy indication strategy covering epidemiology, GLUL biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Acute-on-chronic liver failure indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…

2026 Hereditary hemorrhagic telangiectasia liver disease indication strategy covering epidemiology, ACVRL1 biology, active trials, transactions, unmet need,…

2026 Acute liver failure indication strategy covering epidemiology, HMGB1 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Idiopathic noncirrhotic portal hypertension indication strategy covering epidemiology, Endothelin biology, active trials, transactions, unmet need,…

2026 Sinusoidal obstruction syndrome indication strategy covering epidemiology, PAI-1 biology, active trials, transactions, unmet need, competition and market…

2026 Budd-Chiari syndrome indication strategy covering epidemiology, JAK2 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Portal vein thrombosis indication strategy covering epidemiology, FXI biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Congenital hepatic fibrosis indication strategy covering epidemiology, PKHD1 biology, active trials, transactions, unmet need, competition and market…

2026 Alpha-1 antitrypsin deficiency liver disease indication strategy covering epidemiology, SERPINA1 biology, active trials, transactions, unmet need,…